Caterina Giannini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Caterina Giannini has a total of 944 co-authors. Here are the top co-authors by number of shared publications:
- Rachael A. Vaubel
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA
10 shared publications - Aditya Raghunathan
Department of Laboratory Medicine and Pathology Mayo Clinic Rochester Minnesota USA
9 shared publications Fausto J. Rodriguez
Department of Pathology, Johns Hopkins Hospital, Baltimore, MD
9 shared publications- Evanthia Galanis
Mayo Clinic, Rochester, USA
8 shared publications - Cristiane M. Ida
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, USA
7 shared publications Alissa Caron
Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, MN
6 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Wiley in Brain Pathology
Circumscribed Meningeal Melanocytic Neoplasms: CNS WHO Grade, Molecular Profile, and Clinical Outcomes
Circumscribed meningeal melanocytic neoplasms (CMMNs) represent a spectrum of rare central nervous system (CNS) tumors. Knowledge of their clinical behavior and molecular correlates remains limited. In this single‐institution retrospective study, we analyzed 31 patients (14 male, 17 female; median age, 59 years) diagnosed with CMMN between 2004 and 2025. In this patient cohort, based on the current World Health Organization Central Nervous System Tumor Classification (WHO CNS5) criteria, the majority of cases (18, 58.1%) fell into the intermediate‐grade melanocytic tumor (IMT) category based on histology, with either increased mitotic activity, CNS invasion, or both; 7 (22.6%) were melanocytomas, 5 (16.1%) melanomas, and 1 (3.2%) indeterminate case because of limited tissue. By next‐generation sequencing, mutations were identified in GNAQ/GNA11 in 21/24 cases, BAP1 in 5/23 (2 IMT, 3 melanoma), EIF1AX in 9/21 (1 melanocytoma, 8 IMT), and SF3B1 in 3/23 (2 IMT, 1 melanoma). Primary sites were spinal (20), posterior fossa (6), and supratentorial (5). During follow‐up, progression was observed in 5/6 melanocytomas, 9/13 IMTs, and 4/5 melanomas, suggesting a high frequency of progression across all groups. Two‐year progression‐free survival was 83.3% (95% confidence interval [CI], 53.5%–100.0%) for melanocytoma, 55.9% (95% CI, 26.7%–85.2%) for IMT, and 25.0% (95% CI, 0.0%–67.4%) for melanoma. Five‐year overall survival (OS) was 80.0% (95% CI, 44.9%–100.0%) for melanocytoma, 65.3% (95% CI, 37.0%–93.6%) for IMT, and 0.0% for melanoma. OS was significantly worse in melanoma compared with melanocytoma ( p = 0.002). BAP1 mutation correlated with worse OS (hazard ratio 8.73, p = 0.006). Upfront maximal safe resection appeared to be associated with improved outcomes in selected patients, whereas radiotherapy and systemic therapy did not demonstrate clear additional benefit in this cohort. In summary, our study shows that all CMMNs, irrespective of grade, have a high propensity to recur and melanoma histology and BAP1 mutation are associated with significantly worse OS.
- 15 September 2026
- Published by Wiley in Brain Pathology
Open AccessCircumscribed Meningeal Melanocytic Neoplasms: CNS WHO Grade, Molecular Profile, and Clinical Outcomes
Circumscribed meningeal melanocytic neoplasms (CMMNs) represent a spectrum of rare central nervous system (CNS) tumors. Knowledge of their clinical behavior and molecular correlates remains limited. In this single‐institution retrospective study, we analyzed 31 patients (14 male, 17 female; median age, 59 years) diagnosed with CMMN between 2004 and 2025. In this patient cohort, based on the current World Health Organization Central Nervous System Tumor Classification (WHO CNS5) criteria, the majority of cases (18, 58.1%) fell into the intermediate‐grade melanocytic tumor (IMT) category based on histology, with either increased mitotic activity, CNS invasion, or both; 7 (22.6%) were melanocytomas, 5 (16.1%) melanomas, and 1 (3.2%) indeterminate case because of limited tissue. By next‐generation sequencing, mutations were identified in GNAQ/GNA11 in 21/24 cases, BAP1 in 5/23 (2 IMT, 3 melanoma), EIF1AX in 9/21 (1 melanocytoma, 8 IMT), and SF3B1 in 3/23 (2 IMT, 1 melanoma). Primary sites were spinal (20), posterior fossa (6), and supratentorial (5). During follow‐up, progression was observed in 5/6 melanocytomas, 9/13 IMTs, and 4/5 melanomas, suggesting a high frequency of progression across all groups. Two‐year progression‐free survival was 83.3% (95% confidence interval [CI], 53.5%–100.0%) for melanocytoma, 55.9% (95% CI, 26.7%–85.2%) for IMT, and 25.0% (95% CI, 0.0%–67.4%) for melanoma. Five‐year overall survival (OS) was 80.0% (95% CI, 44.9%–100.0%) for melanocytoma, 65.3% (95% CI, 37.0%–93.6%) for IMT, and 0.0% for melanoma. OS was significantly worse in melanoma compared with melanocytoma ( p = 0.002). BAP1 mutation correlated with worse OS (hazard ratio 8.73, p = 0.006). Upfront maximal safe resection appeared to be associated with improved outcomes in selected patients, whereas radiotherapy and systemic therapy did not demonstrate clear additional benefit in this cohort. In summary, our study shows that all CMMNs, irrespective of grade, have a high propensity to recur and melanoma histology and BAP1 mutation are associated with significantly worse OS.
- Open Access
- 1 July 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (4) , e200607
Immunity Gone Viral
Subacute cognitive decline and imbalance in aquaporin-4-antibody-seropositive neuromyelitis optica spectrum disorder (AQP4+NMOSD) treated with mycophenolate has a broad differential diagnosis, including cerebral involvement of AQP4+NMOSD, infections, or other complications of immunosuppression. In this article, we highlight the diagnostic and treatment approach in a patient with AQP4+NMOSD who developed multifocal brain lesions.
- 1 July 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (4) , e200607
Open AccessImmunity Gone Viral
Subacute cognitive decline and imbalance in aquaporin-4-antibody-seropositive neuromyelitis optica spectrum disorder (AQP4+NMOSD) treated with mycophenolate has a broad differential diagnosis, including cerebral involvement of AQP4+NMOSD, infections, or other complications of immunosuppression. In this article, we highlight the diagnostic and treatment approach in a patient with AQP4+NMOSD who developed multifocal brain lesions.
- Open Access
- 1 July 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (4) , e200573
Inside the Heterogeneity of Primary CNS Vasculitis
Primary CNS vasculitis (PCNSV) is a heterogeneous condition. This study examines a large cohort with long-term follow-up to identify potential disease subsets. We retrospectively analyzed 216 patients with PCNSV (Mayo Clinic, 1983-2023), using standardized diagnostic criteria, classifying by vessel size, histopathology, and outcomes. Subsets and predictors of functional and therapeutic outcomes were evaluated. Diagnosis was based on cerebral angiography in 142 patients and histologically confirmed in 74. Isolated small vessel involvement was positively associated with mass-lesion presentation (odds ratio [OR] 19.38, p = 0.02), meningeal-enhancing lesions (OR 39.10, p < 0.0001), elevated CSF protein (OR 4.04, p = 0.03), and β-amyloid vascular deposits (OR 23.43, p = 0.0001), but negatively with focal manifestations (OR 0.32, p = 0.04) and cerebral infarcts (OR 0.22, p = 0.003). Lymphocytic vasculitis was linked to younger age at diagnosis (p = 0.006), longer symptom-to-diagnosis interval (p = 0.05), more seizures (p = 0.04), and lower disability (p = 0.003) and mortality (p = 0.008). Necrotizing vasculitis was associated with intracranial hemorrhage (p = 0.008). Two or more relapses occurred in 12.7%, associated with histologic diagnosis (OR 3.15, p = 0.009) and inversely with gadolinium-enhanced lesions (OR 0.33, p = 0.01). Therapy response occurred in 82.9%, long-term remission in 23.6%. Cerebral infarcts, especially multiple, were associated with poor therapy response (OR 0.11, p = 0.03). Histologic diagnosis was inversely associated with long-term remission (OR 0.44, p = 0.03), whereas aspirin use was positively associated (OR 2.8, p = 0.002). A rapidly progressive course occurred in 13.4% of patients and was linked to increasing age (OR 1.34/10 years, p = 0.04), cognitive dysfunction (OR 5.59, p = 0.02), cerebral infarctions (OR 5.02, p = 0.004), and large vessel involvement (OR 3.51, p = 0.02). Gadolinium-enhanced lesions (OR 0.36, p = 0.04) and aspirin (OR 0.42, p = 0.08) were protective. Mortality (21.3%) was associated with older age (HR 1.42, p = 0.002), cognitive dysfunction (HR 3.93, p = 0.006), and cerebral infarctions (HR 1.94, p = 0.03). PCNSV heterogeneity, driven by vessel size and histology, affects presentation and outcomes; our findings offer insights to improve diagnosis and treatment.
- 1 July 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (4) , e200573
Open AccessInside the Heterogeneity of Primary CNS Vasculitis
Primary CNS vasculitis (PCNSV) is a heterogeneous condition. This study examines a large cohort with long-term follow-up to identify potential disease subsets. We retrospectively analyzed 216 patients with PCNSV (Mayo Clinic, 1983-2023), using standardized diagnostic criteria, classifying by vessel size, histopathology, and outcomes. Subsets and predictors of functional and therapeutic outcomes were evaluated. Diagnosis was based on cerebral angiography in 142 patients and histologically confirmed in 74. Isolated small vessel involvement was positively associated with mass-lesion presentation (odds ratio [OR] 19.38, p = 0.02), meningeal-enhancing lesions (OR 39.10, p < 0.0001), elevated CSF protein (OR 4.04, p = 0.03), and β-amyloid vascular deposits (OR 23.43, p = 0.0001), but negatively with focal manifestations (OR 0.32, p = 0.04) and cerebral infarcts (OR 0.22, p = 0.003). Lymphocytic vasculitis was linked to younger age at diagnosis (p = 0.006), longer symptom-to-diagnosis interval (p = 0.05), more seizures (p = 0.04), and lower disability (p = 0.003) and mortality (p = 0.008). Necrotizing vasculitis was associated with intracranial hemorrhage (p = 0.008). Two or more relapses occurred in 12.7%, associated with histologic diagnosis (OR 3.15, p = 0.009) and inversely with gadolinium-enhanced lesions (OR 0.33, p = 0.01). Therapy response occurred in 82.9%, long-term remission in 23.6%. Cerebral infarcts, especially multiple, were associated with poor therapy response (OR 0.11, p = 0.03). Histologic diagnosis was inversely associated with long-term remission (OR 0.44, p = 0.03), whereas aspirin use was positively associated (OR 2.8, p = 0.002). A rapidly progressive course occurred in 13.4% of patients and was linked to increasing age (OR 1.34/10 years, p = 0.04), cognitive dysfunction (OR 5.59, p = 0.02), cerebral infarctions (OR 5.02, p = 0.004), and large vessel involvement (OR 3.51, p = 0.02). Gadolinium-enhanced lesions (OR 0.36, p = 0.04) and aspirin (OR 0.42, p = 0.08) were protective. Mortality (21.3%) was associated with older age (HR 1.42, p = 0.002), cognitive dysfunction (HR 3.93, p = 0.006), and cerebral infarctions (HR 1.94, p = 0.03). PCNSV heterogeneity, driven by vessel size and histology, affects presentation and outcomes; our findings offer insights to improve diagnosis and treatment.
- Open Access
- 18 June 2026
- Published by Wiley in Brain Pathology
- p. e70117
Nearest‐neighbors assisted unsupervised analysis for methylation array profiling for central nervous system tumors
The NN method identifies the five nearest reference dataset neighbors to a tested sample and provides an objective estimation of the tested sample methylation class cluster rather than relying on subjective visualization using dimensionality reduction methods such as UMAP and t-SNE.
- 18 June 2026
- Published by Wiley in Brain Pathology
- p. e70117
Open AccessNearest‐neighbors assisted unsupervised analysis for methylation array profiling for central nervous system tumors
The NN method identifies the five nearest reference dataset neighbors to a tested sample and provides an objective estimation of the tested sample methylation class cluster rather than relying on subjective visualization using dimensionality reduction methods such as UMAP and t-SNE.
- Open Access
Chromosome-arm-specific telomere length governs dual modes of structural genome evolution in IDH-mutant astrocytoma
IDH-mutant astrocytomas maintain telomeres through the alternative lengthening of telomeres (ALT) pathway, producing extreme inter-arm telomere length heterogeneity, yet how this heterogeneity shapes structural genome evolution remains unknown. Using Oxford Nanopore long-read sequencing of 20 IDH-mutant astrocytomas, we profiled structural variants (SVs), copy number variants, extrachromosomal DNA (ecDNA) and measured allele-specific telomere lengths from individual long reads. We identified pervasive complex rearrangements, including chromothripsis and foldback events consistent with breakage-fusion-bridge cycles, and widespread ecDNAs. SV breakpoints were enriched at telomeric and centromeric regions regardless of local telomere length, revealing constitutive structural fragility. Arm-level telomere length analysis uncovered a dual-mode model: arms with short telomeres preferentially harbored breakage-associated events, while arms with long ALT-maintained telomeres were enriched for ecDNA and amplification-associated events. These findings identify chromosome-arm-specific telomere length as a determinant of structural genome evolution in ALT-driven tumors.
Open AccessChromosome-arm-specific telomere length governs dual modes of structural genome evolution in IDH-mutant astrocytoma
IDH-mutant astrocytomas maintain telomeres through the alternative lengthening of telomeres (ALT) pathway, producing extreme inter-arm telomere length heterogeneity, yet how this heterogeneity shapes structural genome evolution remains unknown. Using Oxford Nanopore long-read sequencing of 20 IDH-mutant astrocytomas, we profiled structural variants (SVs), copy number variants, extrachromosomal DNA (ecDNA) and measured allele-specific telomere lengths from individual long reads. We identified pervasive complex rearrangements, including chromothripsis and foldback events consistent with breakage-fusion-bridge cycles, and widespread ecDNAs. SV breakpoints were enriched at telomeric and centromeric regions regardless of local telomere length, revealing constitutive structural fragility. Arm-level telomere length analysis uncovered a dual-mode model: arms with short telomeres preferentially harbored breakage-associated events, while arms with long ALT-maintained telomeres were enriched for ecDNA and amplification-associated events. These findings identify chromosome-arm-specific telomere length as a determinant of structural genome evolution in ALT-driven tumors.
- 14 February 2026
- Published by Oxford University Press (OUP) in Journal of Neuropathology & Experimental Neurology
- Vol. 85 (9) , 1041-1044
Dysembryoplastic neuroepithelial tumor: Malignant transformation following radiation
- 14 February 2026
- Published by Oxford University Press (OUP) in Journal of Neuropathology & Experimental Neurology
- Vol. 85 (9) , 1041-1044
Dysembryoplastic neuroepithelial tumor: Malignant transformation following radiation
- 27 January 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (2) , e214478
Clinical Implications of Aberrant Retinoblastoma Signaling in Patients With Grade 4 IDH-Mutant Astrocytoma
The data on the prognostic factors of grade 4 isocitrate dehydrogenase (IDH)-mutant astrocytoma remain limited since the 2021 update of the World Health Organization classification of CNS tumors. This study aimed to investigate prognostic factors affecting survival in grade 4 IDH-mutant astrocytoma. In this retrospective cohort study, medical records of patients diagnosed with grade 4 IDH-mutant astrocytoma between 2002 and 2023 across all 3 Mayo Clinic campuses who received standard radiation/temozolomide were reviewed. Clinical, radiographic, and molecular variables collected included age, sex, midline involvement (infiltration of brainstem, basal ganglia, thalamus, hypothalamus, cerebellum, corpus callosum), O(6)-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation, and cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) deletion. Progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan-Meier methods and Cox proportional hazards regression. Fifty-eight patients were identified (median age: 36 years, 36% female). The median PFS and OS were 2.4 and 6.9 years, respectively. CDKN2A/B homozygous deletion reduced PFS (1.4 vs 4.5 years, hazard ratio [HR] 4.9, 95% CI 2.1-11, p < 0.001) and OS (2.5 vs not reached [NR], HR 3.9, 95% CI 1.3-12, p = 0.018). Midline involvement also reduced PFS (1.4 vs 4.5 years, HR 4.5, 95% CI 1.8-11, p < 0.001) and OS (2.4 vs 13 years, HR 8.7, 95% CI 2.4-32, p = 0.001). MGMT promoter hypermethylation improved PFS (4.6 vs 1.3 years, HR 0.15, 95% CI 0.037-0.63, p = 0.009). Multivariable analyses revealed that PFS remained significantly reduced by CDKN2A/B homozygous deletion (HR 4.2, 95% CI 1.7-10, p = 0.002) and midline involvement (HR 2.6, 95% CI 1.0-6.4, p = 0.045). A significant association between CDKN2A/B homozygous deletion and midline involvement was observed (χ2 = 4.3, p = 0.037). Exploratory analyses revealed that all patients with midline involvement demonstrated aberration in retinoblastoma signaling. CDKN2A/B hemizygous deletion/loss of heterozygosity also reduced OS (2.5 years vs NR, HR 4.9, 95% CI 1.0-23, p = 0.044). CDKN2A/B homozygous deletion and midline involvement independently reduce PFS in patients with grade 4 IDH-mutant astrocytoma treated with standard radiation/temozolomide. Furthermore, midline involvement may be associated with aberrant retinoblastoma signaling. These findings suggest that radiographic and molecular features may have potential utility in informing clinical trial stratification and guiding early clinical decision-making. However, our findings are limited by our small sample size, so further validation in larger, prospective cohorts is needed.
- 27 January 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (2) , e214478
Clinical Implications of Aberrant Retinoblastoma Signaling in Patients With Grade 4 IDH-Mutant Astrocytoma
The data on the prognostic factors of grade 4 isocitrate dehydrogenase (IDH)-mutant astrocytoma remain limited since the 2021 update of the World Health Organization classification of CNS tumors. This study aimed to investigate prognostic factors affecting survival in grade 4 IDH-mutant astrocytoma. In this retrospective cohort study, medical records of patients diagnosed with grade 4 IDH-mutant astrocytoma between 2002 and 2023 across all 3 Mayo Clinic campuses who received standard radiation/temozolomide were reviewed. Clinical, radiographic, and molecular variables collected included age, sex, midline involvement (infiltration of brainstem, basal ganglia, thalamus, hypothalamus, cerebellum, corpus callosum), O(6)-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation, and cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) deletion. Progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan-Meier methods and Cox proportional hazards regression. Fifty-eight patients were identified (median age: 36 years, 36% female). The median PFS and OS were 2.4 and 6.9 years, respectively. CDKN2A/B homozygous deletion reduced PFS (1.4 vs 4.5 years, hazard ratio [HR] 4.9, 95% CI 2.1-11, p < 0.001) and OS (2.5 vs not reached [NR], HR 3.9, 95% CI 1.3-12, p = 0.018). Midline involvement also reduced PFS (1.4 vs 4.5 years, HR 4.5, 95% CI 1.8-11, p < 0.001) and OS (2.4 vs 13 years, HR 8.7, 95% CI 2.4-32, p = 0.001). MGMT promoter hypermethylation improved PFS (4.6 vs 1.3 years, HR 0.15, 95% CI 0.037-0.63, p = 0.009). Multivariable analyses revealed that PFS remained significantly reduced by CDKN2A/B homozygous deletion (HR 4.2, 95% CI 1.7-10, p = 0.002) and midline involvement (HR 2.6, 95% CI 1.0-6.4, p = 0.045). A significant association between CDKN2A/B homozygous deletion and midline involvement was observed (χ2 = 4.3, p = 0.037). Exploratory analyses revealed that all patients with midline involvement demonstrated aberration in retinoblastoma signaling. CDKN2A/B hemizygous deletion/loss of heterozygosity also reduced OS (2.5 years vs NR, HR 4.9, 95% CI 1.0-23, p = 0.044). CDKN2A/B homozygous deletion and midline involvement independently reduce PFS in patients with grade 4 IDH-mutant astrocytoma treated with standard radiation/temozolomide. Furthermore, midline involvement may be associated with aberrant retinoblastoma signaling. These findings suggest that radiographic and molecular features may have potential utility in informing clinical trial stratification and guiding early clinical decision-making. However, our findings are limited by our small sample size, so further validation in larger, prospective cohorts is needed.
- Top Cited Papers
- 22 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (4) , 939-951
Intracranial mesenchymal tumor, FET::CREB fusion-positive: An integrative analysis of 81 cases
Background: Intracranial mesenchymal tumors, FET::CREB fusion-positive (ICMT), show fusions involving FET RNA-binding protein family genes (EWSR1 or FUS) and CREB family of transcription factors (ATF1, CREB1, or CREM). The methylation signature(s), gene expression characteristics, and clinical behavior of this important tumor type require further characterization. Methods: We study the methylation profiles of 81 ICMT cases (61 newly profiled cases and 20 cases from publicly available sources). Clinicopathologic and genomic data were recorded for each case when available. Results: ICMT showed a relatively distinct methylation signature compared to related tumors. Among the 65 cases where fusion types were documented, the identified fusions included EWSR1::ATF1 (25 cases), EWSR1::CREB1 (12 cases), EWSR1::CREM (21 cases), FUS::CREM (3 cases), and SMARCA2::CREM (4 cases). We confirmed the prior description of 2 distinct subgroups of ICMT (subclasses A and B). The majority of the cases belonged to subclass A (n = 69; 85%), which showed a higher median age compared to subclass B patients (26 years vs. 15 years). Subclass B cases (n = 12; 15%) showed shorter progression-free survival (P < 0.01). Gene expression analysis of ICMT showed key overexpressed markers in ICMT, with significant CREM overexpression regardless of fusion type, when compared to either meningioma alone or a larger group of CNS tumors. Conclusions: This work provides further characterization of ICMT as an important CNS mesenchymal neoplasm that is prone to tumor recurrence, showing 2 prognostically relevant methylation subclasses and warranting diagnostic distinction from other epigenetically and histologically related tumors. ICMTs show substantial overexpression of the CREM gene, independent of fusion type.
- 22 January 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (4) , 939-951
Top Cited PapersIntracranial mesenchymal tumor, FET::CREB fusion-positive: An integrative analysis of 81 cases
Background: Intracranial mesenchymal tumors, FET::CREB fusion-positive (ICMT), show fusions involving FET RNA-binding protein family genes (EWSR1 or FUS) and CREB family of transcription factors (ATF1, CREB1, or CREM). The methylation signature(s), gene expression characteristics, and clinical behavior of this important tumor type require further characterization. Methods: We study the methylation profiles of 81 ICMT cases (61 newly profiled cases and 20 cases from publicly available sources). Clinicopathologic and genomic data were recorded for each case when available. Results: ICMT showed a relatively distinct methylation signature compared to related tumors. Among the 65 cases where fusion types were documented, the identified fusions included EWSR1::ATF1 (25 cases), EWSR1::CREB1 (12 cases), EWSR1::CREM (21 cases), FUS::CREM (3 cases), and SMARCA2::CREM (4 cases). We confirmed the prior description of 2 distinct subgroups of ICMT (subclasses A and B). The majority of the cases belonged to subclass A (n = 69; 85%), which showed a higher median age compared to subclass B patients (26 years vs. 15 years). Subclass B cases (n = 12; 15%) showed shorter progression-free survival (P < 0.01). Gene expression analysis of ICMT showed key overexpressed markers in ICMT, with significant CREM overexpression regardless of fusion type, when compared to either meningioma alone or a larger group of CNS tumors. Conclusions: This work provides further characterization of ICMT as an important CNS mesenchymal neoplasm that is prone to tumor recurrence, showing 2 prognostically relevant methylation subclasses and warranting diagnostic distinction from other epigenetically and histologically related tumors. ICMTs show substantial overexpression of the CREM gene, independent of fusion type.
- Open Access
- 17 December 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1) , vdaf260
Comparison of clinical, radiographic and genomic alterations between histologic and molecular glioblastoma, IDH -wildtype
Glioblastoma IDH-wildtype (GBM) may be diagnosed histologically (hGBM) or based on molecular features when microvascular proliferation and histologic necrosis are absent (mGBM). Clinical and radiographic distinction between hGBM and mGBM remains unclear. 101 hGBM cases were matched to 109 mGBM cases by age, sex, year of diagnosis, and TERT promoter mutation (TERTp) status. Clinical outcome, radiographic, and molecular features were compared across mGBM and hGBM. Median time from first MRI to diagnosis was longer for mGBM versus hGBM (34 vs 7 days, p < .001). mGBM more often presented with seizures (51% vs 26%, p < .001), gliomatosis pattern (12% vs 2%, p = .005), basal ganglia involvement (17% vs 0%, p < .001). Contrast enhancement appeared on MRI for 98% (96/98) of hGBM and 50% (54/107) of mGBM (p < .001). mGBM with non-enhancing MRI were rarely multifocal (2% vs 30%, p < .001). mGBM harbored fewer total copy number alterations (median 20 vs 16.5, p = .029), less often had EGFRamp (34% vs 48%, p = .051), isolated chromosome 10 loss (84% vs 96%, p = .013), and CDKN2A/B homozygous deletion (56% vs 77%, p = .005). Median overall survival was longer for mGBM (2.16 vs 1.44 years, p < .001), and for mGBM without MRI contrast enhancement versus hGBM with enhancement (3.11 vs 1.62 years, adjusted p = .003). mGBM without +7/−10 or without CDKN2A/B homozygous deletion had longer survival and time-to-progression versus hGBM with these alterations. mGBM with MRI enhancement may represent undersampled or early/evolving hGBM. mGBM that are non-enhancing, present with seizures, prolonged time to diagnosis, absent CDKN2A/B alteration or +7/−10 may represent other IDH-wildtype entities.
- 17 December 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (1) , vdaf260
Open AccessComparison of clinical, radiographic and genomic alterations between histologic and molecular glioblastoma, IDH -wildtype
Glioblastoma IDH-wildtype (GBM) may be diagnosed histologically (hGBM) or based on molecular features when microvascular proliferation and histologic necrosis are absent (mGBM). Clinical and radiographic distinction between hGBM and mGBM remains unclear. 101 hGBM cases were matched to 109 mGBM cases by age, sex, year of diagnosis, and TERT promoter mutation (TERTp) status. Clinical outcome, radiographic, and molecular features were compared across mGBM and hGBM. Median time from first MRI to diagnosis was longer for mGBM versus hGBM (34 vs 7 days, p < .001). mGBM more often presented with seizures (51% vs 26%, p < .001), gliomatosis pattern (12% vs 2%, p = .005), basal ganglia involvement (17% vs 0%, p < .001). Contrast enhancement appeared on MRI for 98% (96/98) of hGBM and 50% (54/107) of mGBM (p < .001). mGBM with non-enhancing MRI were rarely multifocal (2% vs 30%, p < .001). mGBM harbored fewer total copy number alterations (median 20 vs 16.5, p = .029), less often had EGFRamp (34% vs 48%, p = .051), isolated chromosome 10 loss (84% vs 96%, p = .013), and CDKN2A/B homozygous deletion (56% vs 77%, p = .005). Median overall survival was longer for mGBM (2.16 vs 1.44 years, p < .001), and for mGBM without MRI contrast enhancement versus hGBM with enhancement (3.11 vs 1.62 years, adjusted p = .003). mGBM without +7/−10 or without CDKN2A/B homozygous deletion had longer survival and time-to-progression versus hGBM with these alterations. mGBM with MRI enhancement may represent undersampled or early/evolving hGBM. mGBM that are non-enhancing, present with seizures, prolonged time to diagnosis, absent CDKN2A/B alteration or +7/−10 may represent other IDH-wildtype entities.
- Open Access
- 6 September 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (1) , 130-142
Window of opportunity evaluation of blood–brain barrier permeability heterogeneity within and across high-grade glioma patients
Background: Disruption of the blood–brain barrier (BBB) in high-grade brain tumors is characterized by contrast accumulation on diagnostic imaging. This window of opportunity study correlates contrast imaging features with the tumor distribution of BBB-permeable (levetiracetam) and -impermeable (cefazolin) drugs. Methods: Patients with a clinical diagnosis of a high-grade brain tumor underwent MRI for surgical planning. Cefazolin and levetiracetam were administered prior to skin incision, and serial plasma and image-registered tumor samples were collected during the operation. Drug levels were measured by LC-MS/MS, tissue drug levels were corrected for residual blood, and tumor-to-plasma concentration ratios were calculated. Intraoperative microdialysis was performed in a subset of patients to measure the same two drugs. Results: Tumor (n = 125) and plasma (n = 261) samples were available for analysis from 42 operative cases. Across all samples, the tumor-to-plasma ratio was significantly lower for cefazolin (marginal mean [MM]: 0.15, 95% CI: 0.11–0.19) as compared to levetiracetam (MM: 0.70, 95% CI: 0.64–0.75; P < .001). When compared between contrast-enhancing and non-enhancing regions, tumor-to-plasma ratios for cefazolin varied by 4.4-fold (0.27, 95% CI: 0.20–0.35 vs. 0.06, 95% CI: 0.04–0.08, respectively; P < .001), and varied for levetiracetam by 1.4-fold (0.88, 95% CI: 0.78–0.97 vs. 0.61, 95% CI: 0.55–0.66, respectively; P < .001). These results were confirmed with the intra-operative microdialysis and a population pharmacokinetic analysis. Conclusions: This study demonstrates significant inter- and intra-tumoral heterogeneity in drug delivery for both levetiracetam and cefazolin within high-grade brain tumors that is not necessarily predicted by clinical MR imaging and may reflect tumor-induced changes in both perfusion and BBB integrity.
- 6 September 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (1) , 130-142
Open AccessWindow of opportunity evaluation of blood–brain barrier permeability heterogeneity within and across high-grade glioma patients
Background: Disruption of the blood–brain barrier (BBB) in high-grade brain tumors is characterized by contrast accumulation on diagnostic imaging. This window of opportunity study correlates contrast imaging features with the tumor distribution of BBB-permeable (levetiracetam) and -impermeable (cefazolin) drugs. Methods: Patients with a clinical diagnosis of a high-grade brain tumor underwent MRI for surgical planning. Cefazolin and levetiracetam were administered prior to skin incision, and serial plasma and image-registered tumor samples were collected during the operation. Drug levels were measured by LC-MS/MS, tissue drug levels were corrected for residual blood, and tumor-to-plasma concentration ratios were calculated. Intraoperative microdialysis was performed in a subset of patients to measure the same two drugs. Results: Tumor (n = 125) and plasma (n = 261) samples were available for analysis from 42 operative cases. Across all samples, the tumor-to-plasma ratio was significantly lower for cefazolin (marginal mean [MM]: 0.15, 95% CI: 0.11–0.19) as compared to levetiracetam (MM: 0.70, 95% CI: 0.64–0.75; P < .001). When compared between contrast-enhancing and non-enhancing regions, tumor-to-plasma ratios for cefazolin varied by 4.4-fold (0.27, 95% CI: 0.20–0.35 vs. 0.06, 95% CI: 0.04–0.08, respectively; P < .001), and varied for levetiracetam by 1.4-fold (0.88, 95% CI: 0.78–0.97 vs. 0.61, 95% CI: 0.55–0.66, respectively; P < .001). These results were confirmed with the intra-operative microdialysis and a population pharmacokinetic analysis. Conclusions: This study demonstrates significant inter- and intra-tumoral heterogeneity in drug delivery for both levetiracetam and cefazolin within high-grade brain tumors that is not necessarily predicted by clinical MR imaging and may reflect tumor-induced changes in both perfusion and BBB integrity.